BDCA-2 initiates a pathway leading to inhibition of the type I interferon response and has the potential to suppress inflammation in autoimmune diseases, such as systemic lupus erythematosus (Dzionek et al. The gene discussed is CLEC4C; the disease is systemic lupus erythematosus.